Iris Energy (NASDAQ:IREN – Free Report) had its price objective boosted by HC Wainwright from $13.00 to $16.00 in a research ...

Outlook Therapeutics (NASDAQ:OTLK – Get Free Report)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a report ...

H.C. Wainwright lowered the firm’s price target on Splash Beverage (SBEV) to 50c from $1 and keeps a Buy rating on the shares ...

Fintel reports that on November 26, 2024, HC Wainwright & Co. downgraded their outlook for Poseida Therapeutics ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

H.C. Wainwright analyst Matthew Caufield initiated coverage of Immunic (IMUX) with a Buy rating and $10 price target The firm likes the ...

Fintel reports that on November 25, 2024, HC Wainwright & Co. initiated coverage of Sarepta Therapeutics (LSE:0L35) with a Sell recommendation. As of November 21, 2024, the average one-year price ...

HC Wainwright sets an $18 target on Vanda Pharmaceuticals amid a 30% discount to cash reserves. Vanda's portfolio could reach key clinical and regulatory milestones within 6–18 months.

Fintel reports that on November 25, 2024, HC Wainwright & Co. initiated coverage of Sarepta Therapeutics (NasdaqGS:SRPT) with a Sell recommendation. As of November 21, 2024, the average one-year ...

HC Wainwright initiated coverage on Vanda Pharmaceuticals, Inc. (NASDAQ:VNDA), a commercial-stage biopharmaceutical firm primarily focusing on neurological and neuropsychiatry disorders.